Perspective Therapeutics, Inc. — Director's Dealing 2023

Feb 13, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Isoray, Inc. (ISR)
CIK: 0000728387
Period of Report: 2023-02-03

Reporting Person: Spoor Johan M. (Director, CEO)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	37572	Direct
Common Stock	60000	Indirect
Common Stock	10000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (right to buy)	$	2032-02-13	Common Stock (8454757)		Direct

Footnotes

F1: Fully vested as of 2/3/2023 due to acceleration as a result of merger of Viewpoint Molecular Targeting, Inc. into wholly owned subsidiary of Isoray, Inc. (the "Merger").

F2: Received in exchange for options to acquire 2,672,000 shares of common stock in Viewpoint Molecular Targeting, Inc. at an adjusted exercise price of $0.13 per share pursuant to the terms of the Merger.